title: Malignancy development in lung transplant patients.
abstract: BACKGROUND
  The most common neoplasias among transplant patients are skin cancers and lymphoproliferative disorders.
  
  
  OBJECTIVE
  To characterize lung transplanted recipients who developed malignancies.
  
  
  METHODS
  A retrospective analysis of clinical records of our patients.
  
  
  RESULTS
  Seven patients developed malignancies: skin cancer (n = 5; 71%), and adenocarcinomas of prostatic, gastric, and lung (n = 1 each). One patient developed two hematologic malignancies: T-cell lymphoma and multiple myeloma. Among five patients who died (71%), 3 were due to advanced neoplasia. The mean presentation time was 4.3 years. Skin cancers were resected. The patient with lung adenocarcinoma developed pleural involvement and died. The patient with T-cell lymphoma was treated, but succumbed afterward due to multiple myeloma. The patient with gastric adenocarcinoma died at 3 months after the diagnosis, and the patient with prostate cancer underwent surgery without disease recurrence.
  
  
  CONCLUSIONS
  Malignancies are a late complication of transplant recipients that require a prompt diagnosis and treatment to improve outcomes.
authors.affiliation: Transplant Center, Clinica Las Condes, Santiago, Chile.
authors.forename: M T
authors.initials: MT
authors.lastname: Parada
authors.forename: C
authors.initials: C
authors.lastname: Sepúlveda
authors.forename: A
authors.initials: A
authors.lastname: Alba
authors.forename: A
authors.initials: A
authors.lastname: Salas
mesh_terms: D002677:Chile; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016040:Lung Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000401:mortality; D009369:Neoplasms / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents